David Mott

David Mott has served on Ardelyx’s board of directors since March 2009 and has been the chairperson of the board of directors since March 2014.

David is currently the Chief Executive Officer and Chief Investment Officer of Sphinx Mountain Capital LLC, a family office investment business, and, from February 2020 through August 2025, was a private investor through Mott Family Capital.

David also serves as the chairman of the board for Novavax, Inc. and is a member of the boards of several non-profits. From 2008 to 2020, David was a general partner at New Enterprise Associates (NEA), one of the world’s largest venture capital firms, which invests in companies across all stages in healthcare and technology. At NEA, David led the healthcare investing practice with a personal focus within biotechnology.

Prior to joining NEA, David served as president and chief executive officer and vice chairman of MedImmune from 2000 through 2008, during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion. David joined MedImmune in 1992 and prior to becoming CEO in 2000, he served in various senior roles, including chief operating officer, chief financial officer, and head of business development and strategy.

During the course of his career, David has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has been involved in more than 35 initial public offerings, brought more than a dozen new drugs through development and commercialization, and served on 25 corporate boards.

David holds a Bachelor of Arts degree from Dartmouth College.